Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
- Conditions
- Dyspepsia
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-02-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 359
- Registration Number
- NCT00232037
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Pimecrolimus Cream 1% in Adult Patients With Perioral Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 124
- Registration Number
- NCT00232115
- Locations
- 🇩🇪
Novartis Pharmaceuticals, Nürnberg, Germany
Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 240
- Registration Number
- NCT00231998
- Locations
- 🇯🇵
This study is not being conducted in the United States, Various Cities, Japan
Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis
- First Posted Date
- 2005-10-04
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 160
- Registration Number
- NCT00232011
- Locations
- 🇯🇵
This study is not being conducted in the United States, Various Cities, Japan
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 350
- Registration Number
- NCT00230074
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.
- Conditions
- Bipolar I Disorder
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 132
- Registration Number
- NCT00228059
- Locations
- 🇺🇸
Investigational Site, Cerritos, California, United States
Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients
- Conditions
- Pediatric Kidney Transplantation
- Interventions
- Drug: basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)Drug: MMF, cyclosporine, steroids
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2010-08-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 212
- Registration Number
- NCT00228020
Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis
- Conditions
- Chronic Hand Dermatitis
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2008-02-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 652
- Registration Number
- NCT00226707
"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure
- Conditions
- Heart Failure
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 280
- Registration Number
- NCT00219011
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
- Conditions
- Hypertension
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 493
- Registration Number
- NCT00219115
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States